Marufjon S. Norkulov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marufjon S. Norkulov has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Rustam I. Turakulov
Tashkent State Medical University, Tashkent, Uzbekistan Clinical study site: Republican Specialized Scientific-Practical Medical Center of Cardiology, Qarshi Branch, Uzbekistan
1 shared publication- Rustam Turakulov
Department of Internal Medicine in Family Medicine Tashkent State Medical University Tashkent Uzbekistan
1 shared publication
Latest Publications
- 26 September 2026
- Published by The Pinnacle International Journals in International Journal of Medical Science and Dental Health
- Vol. 12 (09) , 245-252
Six-Month Metabolic, Inflammatory, and Elastographic Outcomes with Adjunctive Ademetionine After Coronary Artery Bypass Grafting in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) frequently coexists with advanced coronary artery disease. Coronary artery bypass grafting (CABG) may produce transient hepatic injury and systemic inflammation, while residual metabolic-inflammatory abnormalities can persist during follow-up. Objective: To evaluate six-month metabolic, inflammatory, and liver-elastography outcomes in patients with stable exertional angina and MAFLD receiving standard post-CABG therapy with or without adjunctive ademetionine. Methods: This comparative cohort analysis included 100 patients with stable exertional angina and MAFLD who underwent CABG for multivessel coronary artery disease. After CABG, 50 patients received standard therapy alone and 50 received standard therapy plus ademetionine (400 mg intravenously daily for 10 days, followed by 500 mg orally twice daily for 6 months). Serum adiponectin, leptin, ghrelin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and liver elastography were evaluated. Perioperative routine laboratory changes were also summarized from the source dissertation. Results: At six months, adjunctive ademetionine was associated with higher adiponectin (7.2 ± 0.16 vs. 4.7 ± 0.18 µg/mL; P < 0.001) and ghrelin (693.8 ± 17.5 vs. 523.9 ± 16.9 pg/mL; P < 0.001), and with lower leptin (22.2 ± 0.5 vs. 29.2 ± 0.6 ng/mL; P < 0.001), IL-6 (8.4 ± 0.4 vs. 11.1 ± 0.3 pg/mL; P < 0.001), and TNF-α (11.5 ± 0.4 vs. 15.1 ± 0.44 pg/mL; P < 0.001). Liver stiffness was lower with ademetionine (Young modulus 7.2 ± 0.1 vs. 8.86 ± 0.09 kPa; P < 0.001), as was the reported fibrosis grade (1.50 ± 0.12 vs. 1.92 ± 0.12; P < 0.05). Conclusion: In patients with MAFLD after CABG, adjunctive ademetionine was associated with a more favorable six-month adipokine, inflammatory, and elastographic profile. Because random allocation and baseline comparability of the two treatment subgroups were not documented in the source dissertation, these findings should be interpreted as associative and require prospective randomized validation.
- 26 September 2026
- Published by The Pinnacle International Journals in International Journal of Medical Science and Dental Health
- Vol. 12 (09) , 245-252
Six-Month Metabolic, Inflammatory, and Elastographic Outcomes with Adjunctive Ademetionine After Coronary Artery Bypass Grafting in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) frequently coexists with advanced coronary artery disease. Coronary artery bypass grafting (CABG) may produce transient hepatic injury and systemic inflammation, while residual metabolic-inflammatory abnormalities can persist during follow-up. Objective: To evaluate six-month metabolic, inflammatory, and liver-elastography outcomes in patients with stable exertional angina and MAFLD receiving standard post-CABG therapy with or without adjunctive ademetionine. Methods: This comparative cohort analysis included 100 patients with stable exertional angina and MAFLD who underwent CABG for multivessel coronary artery disease. After CABG, 50 patients received standard therapy alone and 50 received standard therapy plus ademetionine (400 mg intravenously daily for 10 days, followed by 500 mg orally twice daily for 6 months). Serum adiponectin, leptin, ghrelin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and liver elastography were evaluated. Perioperative routine laboratory changes were also summarized from the source dissertation. Results: At six months, adjunctive ademetionine was associated with higher adiponectin (7.2 ± 0.16 vs. 4.7 ± 0.18 µg/mL; P < 0.001) and ghrelin (693.8 ± 17.5 vs. 523.9 ± 16.9 pg/mL; P < 0.001), and with lower leptin (22.2 ± 0.5 vs. 29.2 ± 0.6 ng/mL; P < 0.001), IL-6 (8.4 ± 0.4 vs. 11.1 ± 0.3 pg/mL; P < 0.001), and TNF-α (11.5 ± 0.4 vs. 15.1 ± 0.44 pg/mL; P < 0.001). Liver stiffness was lower with ademetionine (Young modulus 7.2 ± 0.1 vs. 8.86 ± 0.09 kPa; P < 0.001), as was the reported fibrosis grade (1.50 ± 0.12 vs. 1.92 ± 0.12; P < 0.05). Conclusion: In patients with MAFLD after CABG, adjunctive ademetionine was associated with a more favorable six-month adipokine, inflammatory, and elastographic profile. Because random allocation and baseline comparability of the two treatment subgroups were not documented in the source dissertation, these findings should be interpreted as associative and require prospective randomized validation.
- Open Access
- 12 August 2026
- Published by LLC Scienceproblems Team in MedicineProblems.uz-Topical Issues of Medical Sciences
- Vol. 4 (7) , 73-84
MIOKARD REVASKULYARIZATSIYASIDAN KEYIN METABOLIK ASSOTSIIRLANGAN JIGARNING YOG‘LI KASALLIGI MAVJUD BEMORLARDA ADIPOKIN-SITOKIN DISBALANSI VA JIGAR ELASTIKLIGI DINAMIKASI: GEPATOPROTEKTOR KORREKSIYANING SAMARADORLIGI
Bilan komorbidlikda kechgan bemorlarda aortokoronar shuntlash (AKSh) amaliyotining jigar funksional holati, adipokin-sitokin muvozanati va to‘qima elastikligiga ta’sirini baholash hamda gepatoprotektor korreksiyaning samaradorligini aniqlash. Materiallar va usullar. Ko‘p tomirli koronar zararlanish aniqlanib AKSh o‘tkazilgan 120 nafar bemor tekshirildi: asosiy guruh – stenokardiya MAJYOK bilan kechgan 100 bemor, nazorat guruhi – jigar patologiyasi aniqlanmagan 20 bemor. Ko‘rsatkichlar amaliyotdan oldin, undan 2 kun va 6 oy keyin baholandi. Asosiy guruh 6 oylik davo rejimiga ko‘ra ikkiga ajratildi (standart davo, n=50; standart davo + ademetionin, n=50). Natijalar. Amaliyotdan oldin asosiy guruhda MELD (8,9±0,23 va 7,6±0,2), FLI (77,3±0,74 va 22,7±0,18), leptin (27,7±0,7 va 17,5±0,9 ng/ml), IL-6 (9,2±0,4 va 5,4±0,4 pg/ml), α-O‘NO (12,3±0,45 va 7,4±0,37 pg/ml) va Yung moduli medianasi (8,62±0,17 va 5,53±0,2 kPa) ishonchli yuqori, adiponektin (5,4±0,14 va 6,9±0,31 mkg/ml) hamda grelin (564,5±14,4 va 661,7±28,9 pg/ml) ishonchli past bo‘ldi (p<0,01–0,001). Amaliyotdan keyingi 2-kunda sitolitik, xolestatik va yallig‘lanish ko‘rsatkichlari oshdi; 6-oyga kelib an’anaviy laborator ko‘rsatkichlar me’yorlashdi, ammo adiponektin (4,7±0,18 mkg/ml), leptin (29,2±0,6 ng/ml), IL-6 (11,1±0,3 pg/ml), α-O‘NO (15,1±0,44 pg/ml) va Yung moduli medianasi (8,86±0,09 kPa) boshlang‘ich darajaga qaytmadi. Ademetionin qo‘shilgan kompleks davo ushbu ko‘rsatkichlarning barchasini ishonchli yaxshiladi (p<0,05–0,001). Xulosa. MAJYOK fonida o‘tkazilgan AKSh amaliyoti an’anaviy laborator ko‘rsatkichlar me’yorlashganidan keyin ham saqlanadigan subklinik gepatometabolik va yallig‘lanish buzilishlari bilan kechadi; ularni aniqlashda adipokin-sitokin paneli va elastometriya axborotli, korreksiyasida esa gepatoprotektor terapiya samarali.
- 12 August 2026
- Published by LLC Scienceproblems Team in MedicineProblems.uz-Topical Issues of Medical Sciences
- Vol. 4 (7) , 73-84
Open AccessMIOKARD REVASKULYARIZATSIYASIDAN KEYIN METABOLIK ASSOTSIIRLANGAN JIGARNING YOG‘LI KASALLIGI MAVJUD BEMORLARDA ADIPOKIN-SITOKIN DISBALANSI VA JIGAR ELASTIKLIGI DINAMIKASI: GEPATOPROTEKTOR KORREKSIYANING SAMARADORLIGI
Bilan komorbidlikda kechgan bemorlarda aortokoronar shuntlash (AKSh) amaliyotining jigar funksional holati, adipokin-sitokin muvozanati va to‘qima elastikligiga ta’sirini baholash hamda gepatoprotektor korreksiyaning samaradorligini aniqlash. Materiallar va usullar. Ko‘p tomirli koronar zararlanish aniqlanib AKSh o‘tkazilgan 120 nafar bemor tekshirildi: asosiy guruh – stenokardiya MAJYOK bilan kechgan 100 bemor, nazorat guruhi – jigar patologiyasi aniqlanmagan 20 bemor. Ko‘rsatkichlar amaliyotdan oldin, undan 2 kun va 6 oy keyin baholandi. Asosiy guruh 6 oylik davo rejimiga ko‘ra ikkiga ajratildi (standart davo, n=50; standart davo + ademetionin, n=50). Natijalar. Amaliyotdan oldin asosiy guruhda MELD (8,9±0,23 va 7,6±0,2), FLI (77,3±0,74 va 22,7±0,18), leptin (27,7±0,7 va 17,5±0,9 ng/ml), IL-6 (9,2±0,4 va 5,4±0,4 pg/ml), α-O‘NO (12,3±0,45 va 7,4±0,37 pg/ml) va Yung moduli medianasi (8,62±0,17 va 5,53±0,2 kPa) ishonchli yuqori, adiponektin (5,4±0,14 va 6,9±0,31 mkg/ml) hamda grelin (564,5±14,4 va 661,7±28,9 pg/ml) ishonchli past bo‘ldi (p<0,01–0,001). Amaliyotdan keyingi 2-kunda sitolitik, xolestatik va yallig‘lanish ko‘rsatkichlari oshdi; 6-oyga kelib an’anaviy laborator ko‘rsatkichlar me’yorlashdi, ammo adiponektin (4,7±0,18 mkg/ml), leptin (29,2±0,6 ng/ml), IL-6 (11,1±0,3 pg/ml), α-O‘NO (15,1±0,44 pg/ml) va Yung moduli medianasi (8,86±0,09 kPa) boshlang‘ich darajaga qaytmadi. Ademetionin qo‘shilgan kompleks davo ushbu ko‘rsatkichlarning barchasini ishonchli yaxshiladi (p<0,05–0,001). Xulosa. MAJYOK fonida o‘tkazilgan AKSh amaliyoti an’anaviy laborator ko‘rsatkichlar me’yorlashganidan keyin ham saqlanadigan subklinik gepatometabolik va yallig‘lanish buzilishlari bilan kechadi; ularni aniqlashda adipokin-sitokin paneli va elastometriya axborotli, korreksiyasida esa gepatoprotektor terapiya samarali.